Adam Lang speaks to Ben Willee, General Manager and Media Director of Spinach advertising agency, about what's happening in the world of advertising and media.

Adam Lang speaks to Ben Willee, General Manager and Media Director of Spinach advertising agency, about what's happening in the world of advertising and media.

Daily business news for people who make their own decisions, with business journalist Sean Aylmer and Michael Thompson. Find out more at https://fearandgreed.com.au

Daily business news for people who make their own decisions, with business journalist <a href="https://www.linkedin.com/in/sean-aylmer-9922068/" data-saferedirecturl="https://www.google.com/url?q=https://www.linkedin.com/in/sean-aylmer-9922068/&amp;source=gmail&amp;ust=1689199223540000&amp;usg=AOvVaw0wu3ezGEfBZFYspJbTTaYL">Sean Aylmer</a> and <a href="https://www.linkedin.com/in/mcwthompson/" data-saferedirecturl="https://www.google.com/url?q=https://www.linkedin.com/in/mcwthompson/&amp;source=gmail&amp;ust=1689199223540000&amp;usg=AOvVaw08pZ8jZ88rHJgCfbHkTr5k">Michael Thompson</a>. Find out more at <a href="https://protect-au.mimecast.com/s/7AmQCOMxmAtl5q0qiE-KY7?domain=fearandgreed.com.au/" data-saferedirecturl="https://www.google.com/url?q=https://protect-au.mimecast.com/s/7AmQCOMxmAtl5q0qiE-KY7?domain%3Dfearandgreed.com.au/&amp;source=gmail&amp;ust=1689199223540000&amp;usg=AOvVaw1DLq_FuqjEt3HC-ZK1704H">https://fearandgreed.com.au</a>

Fear and Greed is Australia's most popular business podcast.

FEAR & GREED | Business News

Daily business news for people who make their own decisions, with business journalist <a href="https://www.linkedin.com/in/sean-aylmer-9922068/">Sean Aylmer</a> and <a href="https://www.linkedin.com/in/mcwthompson/">Michael Thompson</a>. Find out more at <a href="https://protect-au.mimecast.com/s/7AmQCOMxmAtl5q0qiE-KY7?domain=fearandgreed.com.au/">https://fearandgreed.com.au</a>

Sunday Feature: Advertising, media, Olympics & more

Logistics company Brambles, glass bottle manufacturer Orora and waste business Cleanaway - three very different companies, but three fascinating stories. 

Jakob Cakarnis, Director of Equity Research at Jarden Australia, tells Sean Aylmer what he likes and dislikes about them.

This is Fear & Greed's summer investing series. All information is general in nature - you should seek independent professional advice before making investment decisions.

Logistics company Brambles, glass bottle manufacturer Orora and waste business Cleanaway - three very different companies, but three fascinating stories. Jakob Cakarnis, Director of Equity Research at Jarden Australia, tells Sean Aylmer what he likes and dislikes about them. This is Fear &amp; Greed's summer investing series. All information is general in nature - you should seek independent professional advice before making investment decisions.

Three mid-cap stocks to consider

https://api.omny.fm/orgs/2fb3740d-3436-44af-8cc0-a91900716aa5/clips/abd0df5d-0d83-4a3b-84b0-b24c007d0226/transcript

Sean Aylmer, Michael Thompson and Adam Lang each nominate their top markets story from the year - and choose a winner.

Sean Aylmer, Michael Thompson and Adam Lang each nominate their top markets story from the year - and choose a winner.

Sharemarket records vs end of Magnificent 7 vs Bitcoin booming

https://api.omny.fm/orgs/2fb3740d-3436-44af-8cc0-a91900716aa5/clips/c37b0735-d9f2-4bd3-b532-b24c007cc408/transcript

Guest: Mesoblast founder Silviu Itescu

Original air date: March 9, 2022

ASX-listed biotech Mesoblast is spoken about a lot on Fear and Greed due to its extremely volatile share price. This is largely tied to some big medical breakthroughs they've been working on for a long time.

 

Founder Silviu Itescu discusses the exhaustive and expensive process behind getting critical new drugs developed, tested and approved and the possible announcements that are coming.

Update: Mesoblast's share price increased by 50% in just one day this week after the US FDA gave the green light to another one of its treatments. 

Guest: Mesoblast founder Silviu Itescu
Original air date: March 9, 2022
ASX-listed biotech Mesoblast is spoken about a lot on Fear and Greed due to its extremely volatile share price. This is largely tied to some big medical breakthroughs they've been working on for a long time.
&nbsp;
Founder Silviu Itescu discusses the exhaustive and expensive process behind getting critical new drugs developed, tested and approved and the possible announcements that are coming.
Update: Mesoblast's share price increased&nbsp;by 50% in just one day this week after the&nbsp;US FDA gave the green light to another one of its&nbsp;treatments.&nbsp;

Sunday feature: This Aussie company's share price is up 900% this year

https://api.omny.fm/orgs/2fb3740d-3436-44af-8cc0-a91900716aa5/clips/00445315-d697-45ad-b67a-b24c0079323d/transcript

Sunday Feature: Advertising, media, Olympics & more

In 1 playlist(s)

FEAR & GREED | Business News

Social links

Follow podcast

Recent clips